Programmed Death Ligand-1 Testing in Adenocarcinoma Lung: A Comparative Study of Cell Block versus Biopsy

BACKGROUND: Immunotherapy currently stands as a novel treatment option, specifically in cases of advanced non-small cell lung carcinoma (NSCLC). Expression of programmed death ligand-1 (PD-L1) in tumor cells forms the mainstay for the use of anti-PD-L1 monoclonal antibodies in the treatment of NSCLC...

Descripción completa

Detalles Bibliográficos
Autores principales: Shukla, Saumya, Pandey, Rahul K., Gupta, Vani, Husain, Nuzhat, Gupta, Anurag, Kant, Surya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10697314/
http://dx.doi.org/10.4103/joc.joc_33_22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10697314/
http://dx.doi.org/10.4103/joc.joc_33_22

Ejemplares similares